BioNTech to pay $1.2 billion over vaccine royalties

BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties
BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennyslvania over the payment of royalties related to its COVID-19 vaccine,
COVID: BioNTech to pay $1.2 billion over vaccine royalties
German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate disputes over royalty payments related to its COVID-19 vaccine.
BioNTech to pay Covid-19 vaccine settlements in US
The German pharmaceutical company BioNTech announced on Friday that it has reached settlements in the US to resolve a royalties dispute with the US Na
BioNTech to Pay Up to $1.26B in Covid-19 Vaccine Settlements With NIH, Penn
BioNTech has agreed to pay $1.26 billion across two separate settlements with the National Institutes of Health and the University of Pennsylvania tied to royalties for its Covid-19 vaccine. The German developer of RNA vaccines and immunotherapies,
BioNTech inks $1B settlements with NIH and Penn to resolve COVID vaccine royalty claims
BioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine royalty claims. Read more here.
BioNTech Announces Settlement With National Institutes of Health, University of Pennsylvania Over Royalty Claims
BioNTech (BNTX) on Friday announced separate agreements with the US National Institutes of Health and the University of Pennsylvania to settle royalty claims related to sales of its COVID-19 vaccine co-developed with pharmaceutical giant Pfizer (PFE).
BioNTech to pay $467M in settlement agreement with University of Pennsylvania
In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...
BioNTech SE ADR rises Friday, outperforms market
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.
Here are Morgan Stanley’s key oncology catalysts for 2025
Last year, Moderna ( NASDAQ: MRNA) made headlines with its individualized mRNA cancer vaccine mRNA-4157 (V940), developed ...
BioNTech's Big Moves: $1.2 Billion Settlements and a Game-Changing Cancer Bet
Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.
BioNTech Enters Into Settlements With U.S. Agency, UPenn Over COVID-19 Vaccine Royalties
Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards. Currently, BioNTech's stock is ...
devdiscourse6h
Global Health Developments: From Cancer Breakthroughs to Bird Flu Mutations
Recent health news includes the FDA's approval of an injectable version of Opdivo, a revived lawsuit against Novartis for ...
BioNTech SE ADR falls Thursday, underperforms market
The ADR's fall snapped a three-day winning streak.
Reuters on MSN15d
US FDA lifts partial clinical hold on BioNTech cancer drug study
Dec 13 (Reuters) - BioNTech SE (22UAy.DE), opens new tab said on Friday it has been informed by its partner OncoC4 that the ...
devdiscourse14h
Regulatory Developments in Health: From Cancer Drugs to Vaccine Royalties
Recent developments in health include the FDA approving an injectable version of Opdivo, a revived lawsuit against Novartis ...